Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 22, 769-770 (2023)
The support of Delphine Heenen (KickCancer Foundation) and Patricia Blanc (Imagine for Margo Foundation) is gratefully acknowledged.
Das, S., Rousseau, R. F., Adamson, P. C. & Lo, A. W. The challenge of pediatric oncology: New business models to accelerate innovation. JAMA Oncol. 4, 1274–1280 (2018).
Fernandez, J.-M., Stein, R. M. & Lo, A. W. Commercializing biomedical research through securitization techniques. Nat. Biotechnol. 30, 964–975 (2012).
Feng, M., Gramlich, J. D., & Gupta, S. Special purpose vehicles: Empirical evidence on determinants and earnings management. Account. Rev. 84, 1833–1876 (2009).
Fischer, A., Dewatripont, M. & Goldman, M. Benefit Corporation: a path to affordable gene therapies? Nat. Med. 25, 1813–1814 (2019).
Eichler, H.-G., Kossmeier, M., Zeitlinger, M. & Schwarzer-Daum, B. Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement. Front. Pharmacol. 14, 1074512 (2023).
The authors declare no competing interests.